Abstract: The present invention provides biological compositions and methods for making the same.

Abstract: White blood cell products and storage media for white blood cells are disclosed. The storage medium includes sodium chloride, sodium acetate, sodium citrate, sodium phosphate, magnesium chloride, potassium chloride, sodium bicarbonate, and glucose. White blood cells stored in such medium remain viable for at least up to 72 hours.

Abstract: Methods of growing and harvesting multiple species of phytoplankton are disclosed herein. The method generally includes four steps, namely: (1) collecting phytoplankton seawater containing multiple species of naturally-occurring phytoplankton directly from a source of seawater; (2) adding nutrients to the phytoplankton seawater to proliferate the multiple species of naturally-occurring phytoplankton to a predetermined density; (3) separating the multiple species of naturally-occurring phytoplankton from the phytoplankton seawater to form a phytoplankton concentrate; and (4) collecting the phytoplankton concentrate such that the collected phytoplankton of the phytoplankton concentrate remain in a substantially intact cellular state.

Abstract: The present application discloses methods and apparatus for preparing blood film or smear samples on a fiber surface, staining the test sample, and generating digital cell images of the films or samples for classification and review. The techniques disclosed herein replace conventional microscope slides with fibers when preparing blood film test samples. Using fibers to prepare blood test samples facilitates automation and integration of the various processes involved in hematology analysis. The techniques disclosed herein can be used to improve the accuracy and efficiency of hematology analysis.

Abstract: The present invention discloses multi-purpose metering fluid/rinse reagents for use in automated cellular analyzers that use liquid volumetric metering. The compositions contain a chelating agent, an ionizing salt, optionally a stabilizing ion, a buffer, a non-hemolytic surfactant, and optionally an antimicrobial agent. Advantageously, the compositions produce less than one part-per-million of formaldehyde over the course of one year. Methods for using the compositions are also described.

Abstract: The present invention relates to a composition consisting of Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin. The present invention relates further to the use of the composition for minimizing the cell-damaging effect of radicals and harmful forms of oxygen, in particular of oxygen radicals or reactive oxygen species. The present invention relates to a composition comprising Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin, wherein the composition is administered in a concentration ranging from 10 to 20 mg/kg body weight. The present invention relates further to the composition for use in the treatment and/or prevention of radical and harmful forms of oxygen derived diseases, in particular of oxygen radical or reactive oxygen species derived diseases. The present invention relates further to the composition as a food supplement or dietary supplement.

Abstract: The atmosphere control composition according to the present invention is an atmosphere control composition for use in the culture of cells, which comprises (a) an ascorbic acid component, (b) water, (c) a porous carrier, (d) an aldehyde-removing agent, (e) a transition metal catalyst and/or an alkaline earth metal hydroxide, wherein the aldehyde-removing agent comprises at least one component selected from the group consisting of ethylene urea, urea, arginine, lysine hydrochloride and a polyallylamine. According to the present invention, the atmosphere control composition feasible for preventing the generation of aldehyde can be provided without affecting the oxygen absorption ability and the carbon dioxide generation ability thereof.

Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

Abstract: Provided herein are methods of preventing, lessening or treating pulmonary fibrosis in a subject. The methods comprise delivering an amount of a powdered extracellular matrix (ECM)-derived material to the respiratory system of the subject effective to prevent, lessen or treat pulmonary fibrosis in a subject. Also provided is an apparatus for delivering the powdered ECM-derived material to a subject.

Abstract: Embodiments described herein relate to in vitro cell culture. Embodiments include a substrate having a support layer that includes support molecules having a first region configured to bind to the substrate and having a photo-responsive region configured to change conformation between at least two conformations. In a first conformation of the photo-responsive region, the support molecules are configured to be more accessible to cells. In a second conformation of the photo-responsive region, the support molecules are configured to be less accessible to cells.

Abstract: Embodiments of the disclosure relate to platelet activation and/or aggregation using electric pulses. In one embodiment, a platelet-containing sample is exposed to electric pulses. At least one of the electric pulses has a duration greater than 1 microsecond and a field strength below 50 kV/cm. In another embodiment, the electric pulses may be designed with particular field strengths and durations.

Abstract: Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful products, such as fuels. For example, systems are described that can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy materials, to produce ethanol and/or butanol, e.g., by fermentation. Hydrocarbon-containing materials are also used as feedstocks.

Abstract: Provided are keratin compositions useful in cell culture. In some embodiments the keratins are biocompatible, promote cell growth, promote cell adhesion and provide an excellent substrate for cell culture. Keratin compositions described herein may be used as coatings, gels, three-dimensional scaffolds, additives to cell culture media, microcarriers, etc. The keratin substrates may also be used to deliver cells, e.g., for cell therapy applications.

Abstract: Ear corn is picked from corn fields by ear corn harvesters and transported to a central shelling station associated with an ethanol manufacturing facility. Shelled corn from the central shelling station is processed into ethanol at the ethanol manufacturing facility, and corn cobs from the central shelling station are burned to provide process heat for the ethanol manufacturing process. Energy is conserved and costs are reduced during the picking and shelling of the ear corn and by the burning of cobs for process heat.

Abstract: Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent.

Abstract: A method of drying a biological sample disposed on a substrate is provided. The method comprises providing the substrate comprising a sample loading area and a heat source; activating the heat source for generating heat; heating the substrate at least above 65° C.; and drying the biological sample. A device for storing sample is also provided, wherein the device comprises a substrate for biological sample-storage; and a heating component that generates heat to maintain a temperature of at least above 65° C. The heating component may contain one or more reagents, wherein the reagents generate heat to maintain a temperature of at least above 65° C.

Abstract: A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.

Abstract: The present invention provides a method for inhibiting blood phosphorus level elevation, including administering to a patient in need thereof a composition comprising a lactic acid bacterium as an active ingredient. The method may further include encapsulating the composition comprising a lactic acid bacterium in a capsule. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administrable, and can sufficiently inhibit a blood phosphorus level elevation.

Abstract: The present invention relates to cell wall degradative systems, in particular to systems containing enzymes that bind to and/or depolymerize cellulose, hemicellulose and other carbohydrates. These systems have a number of applications.

Abstract: Process for the enzymatic synthesis of the compound of formula (I), (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)N-methyl methanamine: and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.